ORMP vs. MCRB, BRNS, GNLX, CNTB, MIST, ANIX, RNAC, IOBT, RVPH, and EBS
Should you be buying Oramed Pharmaceuticals stock or one of its competitors? The main competitors of Oramed Pharmaceuticals include Seres Therapeutics (MCRB), Barinthus Biotherapeutics (BRNS), Genelux (GNLX), Connect Biopharma (CNTB), Milestone Pharmaceuticals (MIST), Anixa Biosciences (ANIX), Cartesian Therapeutics (RNAC), IO Biotech (IOBT), Reviva Pharmaceuticals (RVPH), and Emergent BioSolutions (EBS). These companies are all part of the "pharmaceutical preparations" industry.
Oramed Pharmaceuticals (NASDAQ:ORMP) and Seres Therapeutics (NASDAQ:MCRB) are both small-cap medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their earnings, risk, community ranking, analyst recommendations, valuation, institutional ownership, media sentiment, dividends and profitability.
Seres Therapeutics' return on equity of 0.00% beat Oramed Pharmaceuticals' return on equity.
In the previous week, Seres Therapeutics' average media sentiment score of 0.59 beat Oramed Pharmaceuticals' score of 0.00 indicating that Seres Therapeutics is being referred to more favorably in the news media.
Oramed Pharmaceuticals has higher earnings, but lower revenue than Seres Therapeutics. Seres Therapeutics is trading at a lower price-to-earnings ratio than Oramed Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.
Oramed Pharmaceuticals has a beta of 1.81, meaning that its stock price is 81% more volatile than the S&P 500. Comparatively, Seres Therapeutics has a beta of 2.24, meaning that its stock price is 124% more volatile than the S&P 500.
Seres Therapeutics received 207 more outperform votes than Oramed Pharmaceuticals when rated by MarketBeat users. However, 74.82% of users gave Oramed Pharmaceuticals an outperform vote while only 72.40% of users gave Seres Therapeutics an outperform vote.
12.7% of Oramed Pharmaceuticals shares are held by institutional investors. Comparatively, 59.3% of Seres Therapeutics shares are held by institutional investors. 12.0% of Oramed Pharmaceuticals shares are held by insiders. Comparatively, 5.1% of Seres Therapeutics shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.
Seres Therapeutics has a consensus price target of $6.50, suggesting a potential upside of 766.90%. Given Seres Therapeutics' higher possible upside, analysts clearly believe Seres Therapeutics is more favorable than Oramed Pharmaceuticals.
Summary
Seres Therapeutics beats Oramed Pharmaceuticals on 8 of the 15 factors compared between the two stocks.
Get Oramed Pharmaceuticals News Delivered to You Automatically
Sign up to receive the latest news and ratings for ORMP and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding ORMP and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Oramed Pharmaceuticals Competitors List
Related Companies and Tools
